Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca
The initiative will encourage and motivate emerging biotech startups, innovators and entrepreneurs
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
Genext Genomics can now offer comprehensive solutions that support the growth of India’s biotech ecosystem
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Subscribe To Our Newsletter & Stay Updated
